BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1982899)

  • 1. Direct comparison between the ulcer-healing effects of two H(+)-K(+)-ATPase inhibitors, one M1-selective antimuscarinic and one H2 receptor antagonist in the rat.
    Kromer W; Gönne S; Riedel R; Postius S
    Pharmacology; 1990; 41(6):333-7. PubMed ID: 1982899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An acid-independent antiulcer effect of M1 antimuscarinics in the rat.
    Kromer W; Gönne S
    Pharmacology; 1988; 37 Suppl 1():48-53. PubMed ID: 3237766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.
    Hanauer G; Graf U; Meissner T
    Methods Find Exp Clin Pharmacol; 1991; 13(1):63-7. PubMed ID: 1651432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of gastric proton pump inhibitors on gastric secretion and peptic ulcers].
    Okabe S
    Nihon Yakurigaku Zasshi; 1986 Apr; 87(4):351-60. PubMed ID: 2873085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the gastric antisecretory and antiulcer potencies of telenzepine, pirenzepine, ranitidine and cimetidine in the rat.
    Riedel R; Bohnenkamp W; Eltze M; Heintze K; Prinz W; Kromer W
    Digestion; 1988; 40(1):25-32. PubMed ID: 3234616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
    Morozov IA
    Eksp Klin Gastroenterol; 2002; (3):94-100, 122. PubMed ID: 12353402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endoscopic stage classification of peptic ulcer and characterization of the healing process by proton pump inhibitors].
    Karasawa H; Miwa T
    Nihon Rinsho; 1992 Jan; 50(1):74-80. PubMed ID: 1347333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [H2-receptor antagonist-refractory ulcer--its pathophysiology and role of proton-pump inhibitors].
    Arakawa T
    Nihon Rinsho; 1992 Jan; 50(1):122-30. PubMed ID: 1347325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists].
    Asaka M; Kato M; Sato Y; Miyazaki T
    Nihon Rinsho; 1992 Jan; 50(1):104-10. PubMed ID: 1347322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of histamine H2-receptor antagonists and a proton pump inhibitor on the mucosal hydroxyproline content of ethanol-HCl-induced gastric lesions in rats.
    Suzuki T; Tsukamoto Y; Goto H; Hase S; Arisawa T; Asai J
    Digestion; 1992; 51(3):161-7. PubMed ID: 1387856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous evaluation of gastric and duodenal ulcers-healing activities of anti-ulcer agents in rats.
    Segami T; Suzuki Y; Ito M
    Biol Pharm Bull; 1996 Jan; 19(1):53-6. PubMed ID: 8820911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory action of omeprazole on acid formation in gastric glands and on H+,K+-ATPase isolated from human gastric mucosa.
    Elander B; Fellenius E; Leth R; Olbe L; Wallmark B
    Scand J Gastroenterol; 1986 Apr; 21(3):268-72. PubMed ID: 3012768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.
    Shamburek RD; Schubert ML
    Gastroenterol Clin North Am; 1992 Sep; 21(3):527-50. PubMed ID: 1355465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study.
    Schepp W; Classen M
    Scand J Gastroenterol; 1995 Jun; 30(6):511-4. PubMed ID: 7569755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of H+/K+-ATPase in the parietal cell with omeprazole: a new principle of gastric acid inhibition].
    Lamers CB
    Ned Tijdschr Geneeskd; 1985 Apr; 129(15):679-82. PubMed ID: 2986019
    [No Abstract]   [Full Text] [Related]  

  • 18. Biological basis of omeprazole therapy.
    Sachs G; Wallmark B
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():7-18. PubMed ID: 2562365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid blockade by omeprazole or ICI 162846 in a chronic duodenal ulcer model.
    Gompertz RH; Man WK; Li SK; Spencer J; Baron JH; Michalowski AS
    Agents Actions; 1991 May; 33(1-2):161-3. PubMed ID: 1716826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.
    Kromer W; Postius S; Riedel R; Simon WA; Hanauer G; Brand U; Gönne S; Parsons ME
    J Pharmacol Exp Ther; 1990 Jul; 254(1):129-35. PubMed ID: 2164086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.